Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population

Inclusion Criteria:

• Healthy aldults aged 18-44 months;

• Proven legal identity;

• Subjects have the ability to understand and agree to sign the informed consent form.

Exclusion Criteria:

• Armpit temperature of persons with fever on the day of experimental vaccineadministration>37.0 ℃;

• Previous history of tetanus infection;

• Has received tetanus vaccines or vaccines containing tetanus toxoid antigen (DTP,DTP, meningococcal conjugate vaccine, etc.) within the last 10 years, or hasreceived a tetanus immunoglobulin or tetanus antitoxin within the previous 6 months;

• Women who are lactating, pregnant (with a positive urine pregnancy test) or planningto become pregnant within the last 3 months;

• History of asthma, allergy to vaccines or vaccine components, and severe adversereactions to vaccines, such as urticaria, dyspnea, angioedema, or abdominal pain;

• Congenital malformations or developmental disorders, genetic defects, severemalnutrition, etc.;

• Have congenital or acquired immunodeficiency such as HIV infection, lymphoma,leukemia, systemic lupus erythematosus (SLE), juvenile rheumatoid arthritis (JRA);

• Thyroid disease or history of thyroidectomy, asplenia, functional asplenia, aspleniaor splenectomy resulting from any condition;

• Severe chronic diseases,such as severe cardiovascular diseases,hypertension(Systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg) and diabetes that cannot be controlled by drugs, liver or kidneydiseases,malignant tumors, etc;

• Currently suffering from or have suffered from encephalopathy (such as congenitalbrain hypoplasia, brain trauma, brain tumor, cerebral hemorrhage, cerebralinfarction, brain infection, chemical poisoning, etc.); A history of convulsions,epilepsy, psychosis or a family history of psychosis, and other serious neurologicaldisorders;

• Diagnosed abnormal blood coagulation function (e.g. coagulation factor deficiency,coagulation disorders, abnormal platelets) or obvious bruising or coagulationdisorders;

• Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excludingallergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitissuperficial corticosteroid therapy) in the past 6 months;

• A long history of alcohol or drug abuse;

• Receipt of blood products within in the past 3 months;

• Receipt of attenuated live vaccines in the past 14 days;

• Receipt of inactivated or subunit vaccines in the past 7 days;

• Acute onset of various acute diseases or chronic diseases in the last 7 days;

• Participating in clinical studies of other vaccines or drugs;

• According to the investigator's judgment, the subject has any other factors that arenot suitable for participating in the clinical trial.